Showing results (1641-1650 of 1,659) with videos related to

Sort By:
Pageof 166
Blood Cancer Journal|May 9, 2025
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy ConsortiumOren Pasvolsky, Danai Dima, Lei Feng, et al.
Blood Cancer Journal|November 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experienceAimaz Afrough, Danai Dima, Beatrice Razzo, et al.
Biorxiv : the Preprint Server for Biology|December 19, 2025
Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myelomaFrancesco Maura, Ciara L Freeman, Kylee H Maclachlan, et al.
Physical Review Letters|May 21, 2005
Measurement of helicity-dependent photoabsorption cross sections on the neutron from 815 to 1825 MeVH Dutz, K Helbing, J Krimmer, et al.
Blood Cancer Discovery|July 9, 2025
Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U.S. Myeloma Immunotherapy ConsortiumBeatrice M Razzo, Shonali Midha, Andrew J Portuguese, et al.
Physical Review Letters|November 13, 2003
First Measurement of the Gerasimov-Drell-Hearn Sum Rule for 1H from 0.7 to 1.8 GeV at ELSAH Dutz, K Helbing, J Krimmer, et al.
Physical Review Letters|August 25, 2004
Experimental check of the Gerasimov-Drell-Hearn sum rule for 1HH Dutz, K Helbing, J Krimmer, et al.
Blood Cancer Discovery|August 8, 2025
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy ConsortiumBeatrice M Razzo, Shonali Midha, Andrew J Portuguese, et al.
Blood Advances|July 2, 2026
Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell LeukemiaMahmoud R Gaballa, Kelley Julian, Aimaz Afrough, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 20, 2009
Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosisJohn E Landers, Judith Melki, Vincent Meininger, et al.
Pageof 166